Cybin (HELP) Net Margin (2020 - 2023)
Cybin (HELP) posted quarterly Net Margin of 0.0% for Q4 2023, up 20528.04% on a QoQ basis from 0.0% in Q1 2021.
Cybin (HELP) Net Margin (2020 - 2023) Analysis & Trends
Cybin (HELP) has reported Net Margin for 3 consecutive years, with 0.0% the latest figure, recorded in Q4 2023.
- Quarterly Net Margin changed N/A year-over-year to 0.0% in Q4 2023, while the trailing twelve-month figure through Dec 2024 was 0.0% (changed N/A YoY) and the FY2021 annual result came in at 0.03%, changed N/A from the prior year.
- Net Margin climbed to 0.0% in Q4 2023 per HELP's latest filing, from 0.0% in the prior quarter.
- Over the last five years, Net Margin for HELP reached as high as 0.0% in Q4 2023 and fell as low as 8.1% in Q2 2020.
- A 3-year average of 2.7% and a median of 0.0% in 2021 frame the typical range for Net Margin.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 15.02% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 34.53% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 20.17% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 30.33% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Cybin | 28.04 Mn | 28.04 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 0.00% |
| Mar 31, 2021 | 0.00% |
| Jun 30, 2020 | -8.10% |